Nurix Therapeutics, Inc. beat EPS estimates 56% of the time across 16 reported quarters (9 beats, 7 misses), averaging -2.4% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.73 | $-0.81 | -11.0% | Miss | |
| Q1 FY26 | $-0.76 | $-0.79 | -4.0% | Miss | |
| Q4 FY25 | $-0.84 | $-0.82 | +2.4% | Beat | |
| Q3 FY25 | $-0.84 | $-1.03 | -22.6% | Miss | |
| Q2 FY25 | $-0.71 | $-0.52 | +26.8% | Beat | |
| Q1 FY25 | $-0.72 | $-0.67 | +6.9% | Beat | |
| Q4 FY24 | $-0.67 | $-0.75 | -11.9% | Miss | |
| Q3 FY24 | $-0.67 | $-0.67 | +0.0% | Beat | |
| Q2 FY24 | $-0.66 | $-0.71 | -7.6% | Miss | |
| Q1 FY24 | $-0.80 | $-0.76 | +5.0% | Beat | |
| Q4 FY23 | $-0.51 | $-0.77 | -51.0% | Miss | |
| Q3 FY23 | $-0.69 | $-0.68 | +1.4% | Beat |
Back to NRIX overview · NRIX holders · NRIX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.